Aridis pharmaceuticals covid mab ar-712 neutralizes sars-cov-2 delta variant

Los gatos, calif., july 12, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its covid-19 mab cocktail ar-712 binds and neutralizes the delta variant virus sars-cov-2 at a highly effective level (~20ng/ml).

ARDS Ratings Summary

ARDS Quant Ranking